agilon health, inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
agilon health, inc. (AGL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $79.53 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-02-25
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$103.29M.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$18.60M.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$19.60M.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $79.53M.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$393.35M.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$547.14M, a 159.75% decline from fiscal 2021.
- agilon health, inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $915.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-12-31 | $79.53M 10-K · filed 2025-02-25 | |||
| 2023-12-31 | -$393.35M 10-K · filed 2025-02-25 | |||
| 2023-03-31 | -$103.29M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$547.14M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$490.34M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | -$371.16M 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | -$18.60M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $915.73M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $956.81M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $986.62M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$19.60M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$6.52M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$15.69M 10-Q · filed 2021-10-28 | |||
| 2019-12-31 | $67.38M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |